Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

Anchor your business to a stubborn, real-world problem customers cannot ignore. Replace hustle with systems that standardize decisions, data flow and accountability. Ambition isn’t what holds ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

Just two of the nine shoes leading Nike’s reorganized running lineup have yet to release. Both of those come from the Structure franchise, and one has been confirmed for an early 2026 release. The ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...

A study published in Nature Communications presents a way to create deployable structures that transform from compact folded states into expansive configurations with perfectly smooth surfaces.

Some Nike shoes need no introductions. The Structure isn’t one of them. When it comes to daily trainers, the shoe has long run in the shadows of Pegasus and Vomero. But if it’s in need of an ...